Information letter to health care professionals regarding the safe use of the medicinal product ADEL®D. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughts

19.01.2026 390 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо безпеки застосування лікарського засобу АДЕЛЬ®Д. Лікарські засоби, що містять фінастерид (finasteride) та дутастерид (dutasteride): нові заходи щодо мінімізації ризику суїцидальних думокPDF · 385 КБ

Завантажити

Information letter to health care professionals regarding the safe use of the medicinal product ADEL®D. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughts

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals regarding the safe use of the medicinal product ADEL®D. Medicinal products containing finasteride and dutasteride: new measures to minimize the risk of suicidal thoughts

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration